Skip to main content
Clinical Trials/JPRN-UMIN000023039
JPRN-UMIN000023039
Recruiting
未知

Multicenter Clinical Performance Study to evaluate Plasma-based RAS Gene Mutation Testing using OncoBEAM RAS CRC assay (LS52R) of Patients having Progressive or Recurrent Colorectal Cancer

Sysmex corporation0 sites350 target enrollmentJuly 11, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Sysmex corporation
Enrollment
350
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 11, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\)Patients with pathologically confirmed primary colorectal adenocarcinoma
  • 2\)Patients aged 20 or older at the time of the informed consent
  • 3\)Patients who signed informed consent form
  • 4\)Patients whose blood collection is possible before a treatment start
  • 5\)Patients confirmed Stage4 colorectal cancer by imaging findings
  • 6\)Patients with no previous chemotherapy, or patients whose PD or clinical PD was confirmed before starting next treatment

Exclusion Criteria

  • 1\)Patients judged ineligible to participate in the study
  • 2\)Patients registered to the study in the past
  • 3\)Patients with a history of multiple cancer or with a comorbid multiple cancer
  • 4\)Patients with synchronous or metachronous (a disease\-free interval of five years or shorter) double cancer
  • 5\)Patients with histories of treatment using drugs targeting EGFR such as an anti\-EGFR antibody or Regorafenib

Outcomes

Primary Outcomes

Not specified

Similar Trials